AngioDynamics Reports Fiscal 2016 First Quarter Results

Go back to AngioDynamics Reports Fiscal 2016 First Quarter Results

Canaccord Genuity Cuts Price Target on AngioDynamics (ANGO) Following 1Q16

October 9, 2015 8:55 AM EDT

Canaccord Genuity maintained a Buy rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $17.50 (from $19.00), following the company's 1Q16 earnings results. ANGOs salesforce has now converted approximately 45% of Morpheus customers over to BioFlow, with BioFlow PICC sales up 22% during the quarter.... More

Piper Jaffray Cuts Price target on AngioDynamics (ANGO) Following 1Q16 Results

October 9, 2015 8:12 AM EDT

Piper Jaffray maintained a Neutral rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $14.00 (from $18.00), following the company's 1Q16 earnings results. Revenues missed, coming in at $83.7M, and earnings were in line with expectations.

Analyst Thomas Gunderson commented, "ANGO essentially... More

AngioDynamics (ANGO) Reports In-Line Q1 EPS, Offers Q2 and FY16 Guidance

October 8, 2015 4:04 PM EDT

AngioDynamics (NASDAQ: ANGO) reported Q1 EPS of $0.11, in-line with the analyst estimate of $0.11. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $84.7 million.

AngioDynamics sees Q2 2016 EPS of $0.13-$0.15, versus the consensus of $0.16. AngioDynamics sees Q2 2016 revenue of $87-91 million,... More